CL2023000856A1 - Compuestos derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer - Google Patents

Compuestos derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer

Info

Publication number
CL2023000856A1
CL2023000856A1 CL2023000856A CL2023000856A CL2023000856A1 CL 2023000856 A1 CL2023000856 A1 CL 2023000856A1 CL 2023000856 A CL2023000856 A CL 2023000856A CL 2023000856 A CL2023000856 A CL 2023000856A CL 2023000856 A1 CL2023000856 A1 CL 2023000856A1
Authority
CL
Chile
Prior art keywords
cancer
pyrrolo
pyridin
treatment
her2
Prior art date
Application number
CL2023000856A
Other languages
English (en)
Inventor
C Milgram Benjamin
D White Ryan
Jr St Jean David
Guzman-Perez Angel
Original Assignee
Scorpion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scorpion Therapeutics Inc filed Critical Scorpion Therapeutics Inc
Publication of CL2023000856A1 publication Critical patent/CL2023000856A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta descripción proporciona entidades químicas (por ejemplo, un compuesto o una sal farmacéuticamente aceptable, y/o hidrato, y/o cocristal, y/o combinación de fármacos del compuesto) que inhiben el receptor del factor de crecimiento epidérmico (EGFR, ERBB1) y/o el receptor 2 del factor de crecimiento epidérmico humano (HER2, ERBB2). Estas entidades químicas son útiles, por ejemplo, para tratar una condición, enfermedad o trastorno en el que el aumento (por ejemplo, excesivo) de la activación de EGFR y/o HER2 contribuye a la patología y/o síntomas y/o progresión de la condición, enfermedad o trastorno (por ejemplo, cáncer) en un sujeto (por ejemplo, un ser humano). Esta descripción también proporciona composiciones que las contienen, así como métodos para usar y elaborar las mismas.
CL2023000856A 2020-09-23 2023-03-23 Compuestos derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer CL2023000856A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063082324P 2020-09-23 2020-09-23
US202063092970P 2020-10-16 2020-10-16

Publications (1)

Publication Number Publication Date
CL2023000856A1 true CL2023000856A1 (es) 2023-11-17

Family

ID=78135207

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000856A CL2023000856A1 (es) 2020-09-23 2023-03-23 Compuestos derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer

Country Status (11)

Country Link
US (1) US20230364070A1 (es)
EP (1) EP4217070A1 (es)
JP (1) JP7797513B2 (es)
KR (1) KR20230094197A (es)
AU (1) AU2021347288A1 (es)
CA (1) CA3196712A1 (es)
CL (1) CL2023000856A1 (es)
IL (1) IL301532A (es)
MX (1) MX2023003362A (es)
TW (1) TW202229272A (es)
WO (1) WO2022066734A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021330835B2 (en) 2020-08-24 2023-12-14 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
WO2022066835A1 (en) 2020-09-23 2022-03-31 St. Jude Children's Research Hospital, Inc. Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
EP4323356A1 (en) 2021-04-13 2024-02-21 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
WO2023173083A1 (en) * 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
US20250197391A1 (en) 2022-03-24 2025-06-19 Scorpion Therapeutics, Inc. Methods of synthesizing egfr inhibitors
US20250282795A1 (en) * 2022-04-20 2025-09-11 Celyn Therapeutics, Inc. EGFR Inhibitors in cancer treatment
CN121909190A (zh) 2023-06-08 2026-04-21 安塔列斯疗法股份有限公司 1,5-二氢-4H-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗
CN121712773A (zh) * 2023-06-08 2026-03-20 安塔列斯疗法股份有限公司 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗
WO2025049904A1 (en) 2023-08-31 2025-03-06 Scorpion Therapeutics, Inc. Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation
EP4534085A1 (en) 2023-10-03 2025-04-09 Scorpion Therapeutics, Inc. Compounds for use in methods of treating cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906194B2 (en) 2003-10-08 2005-06-14 Massachusetts Instititue Of Technology Fluorescence assay for kinase activity
US7964729B2 (en) 2006-08-28 2011-06-21 Massachusetts Institute Of Technology Sox-based kinase sensor
WO2012087943A2 (en) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
WO2013092512A1 (en) 2011-12-21 2013-06-27 Bayer Intellectual Property Gmbh Substituted benzylpyrazoles
WO2013167698A1 (en) 2012-05-11 2013-11-14 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
US9604980B2 (en) * 2012-11-07 2017-03-28 Nerviano Medical Sciences S.R.L. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
EP2976336A1 (en) 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
EP2976335A1 (en) 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
WO2014176475A2 (en) 2013-04-26 2014-10-30 The Regents Of The University Of Michigan Egfr inhibitors and uses thereof
JP2016526540A (ja) 2013-06-21 2016-09-05 バイエル ファーマ アクチエンゲゼルシャフト 置換ベンジルピラゾール
JP2016525076A (ja) 2013-06-21 2016-08-22 バイエル ファーマ アクチエンゲゼルシャフト 置換されたベンジルピラゾール類
CN105452237A (zh) 2013-06-21 2016-03-30 拜耳制药股份公司 杂芳基取代的吡唑
WO2014202588A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
CA2928998A1 (en) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
EP3143015B1 (en) 2014-05-13 2019-02-20 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
AR100886A1 (es) * 2014-06-17 2016-11-09 Bayer Pharma AG 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
AU2016212230B2 (en) 2015-01-28 2019-09-19 Bayer Pharma Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CA2989469A1 (en) 2015-06-17 2016-12-22 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
US10308629B2 (en) 2015-08-05 2019-06-04 Bayer Pharma Aktiengesellschaft 1H-pyrrol-3-amines
BR112018004175B8 (pt) 2015-09-01 2023-10-31 Taiho Pharmaceutical Co Ltd Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto
EP3390401A1 (en) * 2015-12-16 2018-10-24 Bayer Pharma Aktiengesellschaft Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones
MA46852A (fr) 2016-11-17 2019-09-25 Univ Texas Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20
CN111032655B (zh) 2017-08-31 2022-09-02 达纳-法伯癌症研究所股份有限公司 Egfr和/或her2抑制剂和使用方法
US11339157B1 (en) 2017-10-24 2022-05-24 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CA3091834A1 (en) 2018-02-23 2019-08-29 The Regents Of The University Of Michigan Egfr dimer disruptors and use of the same
WO2019165385A1 (en) 2018-02-23 2019-08-29 Fulton Group N.A., Inc. Inward-firing premix fuel combustion burner
WO2019241715A1 (en) 2018-06-14 2019-12-19 Dana-Farber Cancer Institute, Inc. Cyano quinoline amide compounds as her2 inhibitors and methods of use
WO2019246541A1 (en) 2018-06-21 2019-12-26 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
WO2020216773A1 (en) * 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
GEAP202415804A (en) * 2019-04-24 2024-02-12 Bayer Ag 4h-pyrrolo[3,2-c]pyridin-4-one compounds
EP3958865B1 (en) * 2019-04-24 2025-12-10 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives

Also Published As

Publication number Publication date
MX2023003362A (es) 2023-05-30
TW202229272A (zh) 2022-08-01
JP2023543528A (ja) 2023-10-16
CA3196712A1 (en) 2022-03-31
EP4217070A1 (en) 2023-08-02
IL301532A (en) 2023-05-01
US20230364070A1 (en) 2023-11-16
WO2022066734A1 (en) 2022-03-31
JP7797513B2 (ja) 2026-01-13
KR20230094197A (ko) 2023-06-27
AU2021347288A9 (en) 2023-07-13
AU2021347288A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
CL2023000856A1 (es) Compuestos derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer
CL2023001012A1 (es) Métodos para el tratamiento del cáncer
US11000601B2 (en) Conjugated biological molecules, pharmaceutical compositions and methods
JP6382516B2 (ja) 抗腫瘍アルカロイドを用いる、組み合わせの治療法
MX2024013469A (es) Compuestos heterocíclicos y usos de estos
CL2023003691A1 (es) Derivados de la urea que pueden ser utilizados para tratar el cáncer
CR20230185A (es) Compuestos y su uso en el tratamiento del cáncer
PY2201430A (es) Compuestos y composiciones para tratar condiciones asociadas con la actividad de sting
WO2022072645A3 (en) Pyrrolopyrolidinone and pyrroloazepinone derivatives for use in treating cancer
WO2022133046A3 (en) Compounds and compositions for treating conditions associated with sting activity
PY2301792A (es) Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting
CO2024000448A2 (es) Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncer
CL2024000385A1 (es) Compuestos y composiciones para tratar condiciones asociadas con actividad de sting
WO2022133098A3 (en) Compounds and compositions for treating conditions associated with sting activity
MX2020010121A (es) Compuestos con actividad antitumoral contra celulas de cancer que portan las mutaciones del exon 19 del receptor 2 del factor de crecimiento epidermico humano.
AR123760A1 (es) Métodos para tratar el cáncer
AR132892A1 (es) Métodos para tratar el cáncer
AR132891A1 (es) Métodos para tratar el cáncer
AR126753A1 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
AR126147A1 (es) Derivados de urea para tratar el cáncer
MX2024005997A (es) Antagonistas del receptor de adenosina.
UY39819A (es) Métodos para tratar el cáncer
BR112022003286A2 (pt) Combinação de poziotinibe com inibidores de vegfr2 e métodos de uso da mesma
EA202190523A1 (ru) Замещенные индолы и способы их применения
Goldberg et al. Leukemia Research Reports